English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
| Clinical Publications | Scientific Publications |
| December 2019 | |
| Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEA CML WP (Baccarani M et al. Blood Adv. December, 2019) – open access publication |
Comprehensive analyses of safety and efficacy towards individualizing imatinib dosage in patients with chronic myeloid leukemia (Shin H et al. Int J Hematol, December 2019) (epub ahead of print) |
| Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in CML study (Soverini S et al. Blood, December 2019) (epub ahead of print) |
A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells (Brachet-Botineau M et al. Cancers (Basel), December 2019) |
| Tyrosine kinase inhibitors in leukemia and cardiovascular events: From mechanisms to patient care (Manouchehri A et al. Arterioscler Thromb Vasc Bio, December 2019) (epub ahead of print) – open access publication |
Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia (Ni J et al. Leuk Lymphoma, December 2019) (epub ahead of print) |
|
Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia |
Reconstituion of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation |
| Feasibility study of switching to nilotinib after first-line imatinib in the chronic phase of chronic myeloid leukemia (Chen Y et al. Clin Lymphoma Myeloma Leuk, December 2019) |
Macrophage protects mycoplasma-infected chronic myeloid leukemia cells from NK cell killing (Choo QWW et al. Immunol Cell Biol, December 2019) (epub ahead of print) |
| Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure (Hughes TP et al. N Eng J Med, December 2019) |
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper (Soverini S et al. J Hematol Oncol, December 2019) - OPEN ACCESS |
| Do persons with chronic myeloid leukemia have normal or near normal survival? (Radivoyevitch T et al. Leukemia, December 2019) (epub ahead of print) - OPEN ACCESS |
Chronic myeloid leukemia: The danger of not knowing your BCR-ABL1 transcript (Sharplin K et al. Leuk Res, December 2019) |
| Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: An update (Bavaro L et al. Int J Mol Sci, December 2019) - OPEN ACCESS |
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia (Gupta P et al. Cancer Lett, December 2019) (epub ahead of print) |
| Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: A systematic review and meta-analysis (García-Ferrer M et al. Clin Ther, December 2019) |
The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia (Hillis S et al. Leuk Res, December 2019) (epub ahead of print) |
| Treatment-free remission in chronic myeloid leukemia (Molica M et al. Clin Adv Hematol Oncol, December 2019) |
Blast crisis of chronic myeloid leukemia with plasmacytoid dentritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1 (Xu D et al. Leuk Lymphoma, December 2019) |
| Management of ponatinib in patients with chronic myeloid leukemia with cardiovascular risk factors (Santoro M et al. Chemotherapy, December 2019) (epub ahead of print) |
|
| November 2019 | |
| Sudden blastic transformation in treatment-free remission chronic myeloid leukemia (Alfayez M et al. Br J Haematol, November 2019) |
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission |
| New approaches to molecular monitoring in CML (and other diseases) (Radich J et al. Blood, November 2019) |
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (Lauseker M et al. Am J Hematol, November 2019) |
|
Compexity of chronic-phase CML management after failing a second-generation TKI |
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells (Tanaka A et al. J Exp Med, November 2019) (epub ahead of print) |
| Towards a personalized treatment of patients with chronic myeloid leukemia (Rabian F et al. Curr Hematol Malig Rep, November 2019) (epub ahead of print) |
Role of cancer immunology in chronic myelogenous leukemia (Ureshino H et al. Leuk Res, November 2019) (epub ahead of print) |
| The TKI-free duration after a first discontinuation attempt that failed in CP CML patients is a predictive factor of TKI-free remission after a second attempt (Legros L et al. Blood, November 2019) |
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315l clones in TKI-resistant CML (Schneeweiss-Gleixner M et al. EBioMedicine, November 2019) (epub ahead of print) |
| Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): A FI-LMC STOP 2G-TKI study update (Rea D et al. Blood, November 2019) |
Repurposing drugs in silico methods to target BCR kinase domain in chronic myeloid leukemia (Natarjan A et al. Asian Pac J Cancer Prev, November 2019) http://journal.waocp.org/article_88830.html |
| Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also bEarly management of CML (Shanmunagathan N et al. Curr Hematol Malig Rep, November 2019) (epub ahead of print) |
Druggable biochemical pathways and potential therapeutic alternatives to target leukemia stem cells and eliminate the residual disease in chronic myeloid leukemia |
| Introducing a predictive score for successful treatment-free remission in chronic myeloid leukemia (CML) (Claudiani S et al. Blood, November 2019) |
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia (Lernoux M et al. Biochem Pharmacol, November 2019) (epub ahead of print) |
|
Early management of CML |
The hidden pathogenesis of CML: Is BCR-ABL1 the first event? (Shanmunagathan N, Branford S. Curr Hematol Malig Rep, November 2019) (epub ahead of print) |
| October 2019 | |
| Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia (Franke GN et al. J Mol Diagn, October 2019) (epub ahead of print) |
Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants (Eide CA et al. Cancer Cell, October 2019) |
| Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study (Shah NP et al. Leuk Lymph, October 2019) (epub ahead of print) |
|
| Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type (Baccarani et al. Leukemia, October 2019) |
|
| September 2019 | |
| Prolonged treatment free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations (Claudiani S et al. Haematologica, September 2019) (epub ahead of print) |
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways (Magistroni V et al. Haematologica, September 2019 |
| Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia (Naqvi K et al. Cancer, September 2019) (epub ahead of print) |
Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells (Okabe S et al. Leuk Lymphoma, September 2019) (epub ahead of print) |
| New approaches of molecular monitoring in CML (and other diseases) (Radich J et al. Blood, September 2019) (epub ahead of print) |
KLF4 represses DYRK2 inhibition of self-renewal and survival through c-Myc and p53 in leukemia stem/progenitor cells (Park CS et al. Blood, September 2019) (epub ahead of print) |
| Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy (Efficace F et al. Leukemia, September 2019) (epub ahead of print) |
MiR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation (Huang T et al. Biomed Pharmacother, September 2019) (epub ahead of print) |
| Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt) (Nagafuji K et al. J Hematol, September 2019) (epub ahead of print) |
The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib (Bestach Y et al. Leuk Res, September 2019) (epub ahead of print) |
| Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy (Tiribelli M et al. Ann Hematol, September 2019) |
The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia (Xu H et al. Leuk Lymphoma, September 2019) (epub ahead of print) |
| Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States (Abou Dalle I et al. Cancer Med, September 2019) (epub ahead of print) |
|
| Tyrosine kinase inhibitors in the clinical setting: A conundrum of choices (Bankar A et al. Acta Haematol, September 2019) |
|
|
Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial |
|
| August 2019 | |
| Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (Lauseker M et al. Am J Hematol, August 2019) (epub ahead of print) |
BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis (Kidoguchi K et al. Ann Hematol, August 2019) (epub ahead of print) |
| Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type (Baccarani M et al. Leukemia, August 2019) (epub ahead of print) |
Continuous cytostatic effects of BCR-ABL tyrosine kinase inhibitors (TKI’s) after washout in human leukemic K562 cells (Aoyama T et al. Biol Pharm Bull, August 2019) (epub ahead of print) |
| Treatment patterns and deep molecular response in chronic-phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study (Cortes J et al. Leuk Lymphoma, August 2019) (epub ahead of print) |
Identification of key candidate targets and pathways for the treatment of leukemia using bioinformatics analysis (Li H et al. Mol Genet Genomic Med, August 2019) (epub ahead of print) |
| Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukemia (Ross DM et al. Br J Haematol, August 2019) |
Bone marrow microenvironment: The guardian of leukemia stem cells (Houshmand M et al. World J Stem Cells, August 2019) |
| Treatment patterns and deep molecular response in chronic phase chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study (Cortes J et al. Leuk Lymphoma, August 2019) (epub ahead of print) |
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of surviving and cyclin D1 in chronic myeloid leukemia cells (Moriyama K et al. Int J Hematol, August 2019) (epub ahead of print) |
| Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogenous leukemia – You can do this if you read the instructions (Schiffer CA. Haematologica, August 2019) |
Combined inhibition of MDM2 and BCR-ABL tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model (Carter BZ et al. Haematologica, August 2019) (epub ahead of print) |
| The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia (Aoyama R et al. J Cardiol, August 2019) (epub ahead of print) |
Phosphorylation of Beclin-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia (Yu C et al. Haematologica, August 2019) (epub ahead of print) |
| Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukemia in chronic phase: a prospective observational study in daily clinical practice (Huguet F et al. Br J Haematol, August 2019) (epub ahead of print) |
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of surviving and Cyclin D1 in chronic myeloid leukemia cells (Moriyamo K et al. Int J Hematol, August 2019) (epub ahead of print) |
| Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in real-life practice (Caocci G et al. Ann Hematol, August 2019) |
Targeting small molecule tyrosine kinases by Polyphenols: New move towards anti-tumor drug discovery (Sakle NS et al. Curr Drug Discov Technol, August 2019 (epub ahead of print) |
| New approaches and treatment combinations for the management of chronic myeloid leukemia (Westerweel PE et al. Front Oncol, August 2019) |
|
| FISH versus real-time quantitative PCR for monitoring of minimal residual disease in chronic myeloid leukemia patients with tyrosine kinase inhibitor therapy (Haidary AM et al. Malays J Pathol, August 2019) |
|
| Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase exposure: A Blood or Marrow transplant Survivor Study (BMTSS) Report (Wu J et al. Cancer, August 2019) (epub ahead of print) |
|
| Outcome of very elderly chronic myeloid leukemia patients treated with imatinib frontline (Crugnola M et al. Ann Hematol, August 2019) (epub ahead of print) |
|
| Recommendations from a Portuguese expert group for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients in clinical practice (Almeida A et al. Acta Med Port, August 2019) (epub ahed of print) |
|
| July 2019 | |
| Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome (Berger MG et al. Br J Haematol, July 2019) (epub ahead of print) |
Oncurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments (Sheng G et al. Leuk Lymphoma, July 2019) (epub ahead of print) |
| Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors (Etienne G et al. Cancer Med, July 2019) (epub ahead of print) |
Targeting BCR-ABL 1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation (Burslem GM et al. Cancer Res, July 2019) (epub ahead of print) |
| Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients (Nicolini FE et al. Clin Cancer Res, July 2019) (epub ahead of print) |
Killer immunoglobulin-line receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission (Dumas PY et al. Cancer Med, July 2019) (epub ahead of print) |
| Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test (Kondo T et al. Int J Hematol, June 2019) (epub ahead of print) |
Infliximab together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia (Herrmann O et al. BMC Cancer, July 2019) |
| Digital droplet PCR at the time of TKI discontinuation in chronic phase chronic myeloid patients is predictive of treatment-free remission outcome (Colafigli G et al. Hematol Oncol, July 2019) (epub ahead of print) |
Human BCR-ABL1 induces chronic myeloid leukemia-like disease in zebrafish (Xu M et al. Haematologica, July 2019) (epub ahead of print) |
| True value of second-generation TKI’s as first-line therapy in chronic myeloid leukemia (Andrews CN et al. Lancet Haematol, June 2019) (epub ahead of print) |
Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts (Xue M et al. Leuk Lymphoma, July 2019) (epub ahead of print) |
| Front-line use of tryrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations (Reff MJ et al. J Oncol Pharm Pract, July 2019) (epub ahead of print) |
Determination of serum imatinib and it’s metabolite in patients with chronic myeloid leukemia (Onmaz DE et al. Clin Chim Acta, July 2019) (epub ahead of print) |
| Tyrosine kinase inhibitors available for chronic myeloid leukemia: Efficacy and safety (García-Gutiérrez V et al. Front Oncol, July 2019) |
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in PH+ leukemia and sensitizes for ABL kinase inhibitors (Bahjat M et al. Cell Cycle, July 2019) (epub ahead of print) |
| Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: results from a population-based study (Lauseker M et al. Eur J Haematol, July 2019) (epub ahead of print) |
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/line cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment (Trojani A et al. PLoS One, July 2019) (epub ahead of print) |
| Comparison of BCR-ABL transcript variants between patients with chronic myeloid leukemia and leukemia cell lines (DE Oliveira Sales L et al. In Vivo, July-Aug 2019) |
|
| June 2019 | |
|
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series |
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells (Abraham A et al. J Clin Invest, June 2019) |
| De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukemia (DESTINY): a non-randomized, phase 2 trial (Clark RE et al. Lancet Haematol, June 2019) (epub ahead of print) |
Variant specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Is dPCR the key? (Bernardi S et al. Eur J Haematol, June 2019) (epub ahead of print) |
| Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukemia: a modeling study (Shih YT et al. Lancet Haematol, June 2019) (epub ahead of print) |
Knockdown of ribonucelotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib-based therapy (Liu C et al. Oncol Rep, June 2019) (epub ahead of print) |
| Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia (Dragani M et al. Leuk Lymphoma, June 2019) (epub ahead of print) |
Clinical implications of simultaneous occurrence of variant Philadelphia translocations in chronic myeloid leukemia (Trivedi P et al. J Assoc Genet Technol, 2019) |
| Therapy de-escalation before stopping in chronic myeloid leukemia (Mustjoki S et al. Lancet Haematol, June 2019) (epub ahead of print) |
|
| Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy (Dou X et al. Oncologist, June 2019) (epub ahead of print) |
|
| Is there a role for dose modification of TKI therapy in CML? (Copland M. Curr Hematol Malig Rep, June 2019) (epub ahead of print) |
|
| May 2019 | |
| NCCN Guidelines updates: Discontinuing TKI therapy in the treatment of chronic myeloid leukemia (Shah NP et al. J Natl. Compr Canc Netw, May 2019) |
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib (Kok CH et al. Blood Adv, May 2019) |
| Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data (Breccia M et al. Acta Haematol, May 2019) (epub ahead of print) |
Outcomes of patients with chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy (Boddu P et al. Leuk Lymphoma, May 2019) (epub ahead of print) |
| Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life (Molica M et al. Ann Hematol, May 2019) (epub ahead of print |
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors (Nteliopoulos G et al. Haematologica, May 2019) (epub ahead of print) |
| Patients’ perspective on the definition of cure in chronic myeloid leukemia (Flynn KE et al. Leuk Res, May 2019) |
The proportion of different transcript types in chronic myeloid leukemia: An international review (Baccarani M et al. Leukemia, May 2019) |
| Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors (Jamy O et al. Leuk Res, May 2019) (epub ahead of print) |
Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia |
| Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options (Sundaram DNM et al. Drug Discov Today, May 2019) (epub ahead of print) |
Digital PCR in myeloid malignancies: Ready to replace quantitative PCR? |
| Influence of glutathione S-transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response (Rostami G et al. Mol Genet Genomic Med, May 2019) (epub ahead of print) |
|
| Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo (Jyotsana N et al. Ann Hematol, May 2019) (epub ahead of print) |
|
| Validation of a Drosophila model of wild type and T315l mutated BCR-ABL1 in chronic myeloid leukemia: An effective platform for treatment screening (Al Outa A et al. Haemotologica, May 2019) (epub ahead of print) |
|
| PF-114, a novel selective inhibitor of BCR-ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells (Ivanova ES et al. Int J Oncol, May 2019) (epub ahead of print) |
|
|
|
Chronic myeloid leukemia stem cells |
| April 2019 | |
| A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hemotopoietic cell transplantation (Bezerra ED et al. Leuk Lymphoma, April 2019) |
Antitumor efficacy of arsenal/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors |
| The outcomes of chronic myeloid leukemia patients with molecular warning responses during imatinib treatment according to the European LeukemiaNet 2013 recommendations (Soysal T et al. Clin Lymphoma Myeloma Leuk, April 2019) (epub ahead of print) |
The vascular bone marrow niche influences outcomes in chronic myeloid leukemia via the E-selectin-SCL/TAL1-CD44 axis |
| Patient-reported outcomes in the phase 2 BEFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia (Cortes JE et al. J Cancer Res Clin Oncol, April 2019) (epub ahead of print) |
Modelling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission (Shanmuganathan N et al. Blood, April 2019) (epub ahead of print) |
| Matching-adjusted indirect comparison of bosutinib, dasatinib, and nilotinib on survival and major cytogenetic response for treatment of second-line chronic phase chronic myeloid leukemia (Cortes JE et al. Curr Med Res Opin, April 2019) (epub ahead of print) |
Compound mutations in CML – imaginary bogeyman or real arch-nemesis? (Yeung DT. Leuk Res, April 2019) |
|
Exploring patient decision making regarding discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia |
Variant specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe against cancer qPCR assay |
| Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor (Möbius S et al. J Cancer Res Clin Oncol, April 2019) (epub ahead of print) |
Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia (Wang R et al. Medicine, April 2019) |
|
Anthropometric facts and risk of myeloid leukaemias and myelodysplastic syndromes: a prospective study and meta-analysis |
|
| March 2019 | |
| MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia (Claudiani S et al. Haematologica, March 2019) (epub ahead of print) |
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitors (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) (Wu J et al. Cancer Biol Ther, March 2019) (epub ahead of print) |
|
Lenalidomine maintenance after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukemia |
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis |
| Nilotinib in the treatment of chronic myeloid leukemia (Sacha T et al. Future Oncol, March 2019) |
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation (Uchida E et al. Int J Oncol, March 2019) (epub ahead of print) |
| Analysis of cardiovascular and arteriothrombotic events in chronic-phase CML patients after frontline TKI’s (Jain P et al. Blood Adv, March 2019) |
A synergistic combination against chronic myeloid leukemia: An intra-molecular mechanism of communication in BCR-ABL1 resistance (El Rashedy AA et al. Protein J, March 2019) (epub ahead of print) |
| Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (Score) chart (Caocci G et al. Hematol Oncol, March 2019) (epub ahead of print) |
Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling (Kuepper MK et al. Leukemia, March 2019) (epub ahead of print) |
| Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (Janssen L et al. Leukemia, March 2019) (epub ahead of print) |
Impact of additional chromosomal aberrations on the disease progression of chronic myelogenous leukemia (Krishna Chandran R et al. Front Oncol, March 2019) (epub ahead of print) |
| Incidence of second malignancies in patients with chronic myloid leukemia in the era of tyrosine kinase inhibitors (Sasaki K et al. Int J Hematol, March 2019) (epub ahead of print) |
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact an inclusion of CML patients in stopping trials (Spiess B et al. PLos One, March 2019) |
| Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia (Mauro MJ. Curr Opin Hematol, March 2019) |
Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review) (Lee HR et al. Oncol Rep, March 2019) (epub ahead of print) |
|
Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities |
|
|
Can increased immunogenicity in chronic myeloid leukemia improve outcomes? |
|
|
Can increased immunogenicity in chronic myeloid leukemia improve outcomes? |
|
| February 2019 | |
| Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice (Fava C et al. Haematologica, February 2019) (epub ahead of print) |
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways (Magistroni V et al. Haematologica, February 2019) (epub ahead of print) |
| Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI (Shanmunagathan N et al. Blood Adv, February 2019) |
Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia (Ferri C et al. Gene, February 2019) (epub ahead of print) |
| Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line (Dulucq S et al. Ann Hematol, February 2019) (epub ahead of print) |
PTBP2 exon 10 inclusion is associated with the progression of CML and it is BCR-ABL 1 dependent (Nandagopalan SR et al. Int J Biochem Cell Biol, February 2019) (epub ahead of print) |
| Chronic myeloid leukaemia in pregnancy: call for guidelines (Pallavee P et al. J Obste Gynaecol, February 2019) (epub ahead of print) |
Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale (Furuya D et al. Int J Clin Oncol, February 2019) (epub ahead of print) |
|
The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors |
Imatinib treatments have long-term impact on placentation and embryo survival (Salem W et al. Sci Rep, February 2019) |
| Everolimus in combination with imatinib overcomes resistance in chronic myeloid leukemia (Alves R et al. Med Oncol, February 2019) |
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients |
|
Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis |
High circ_100053 predicts a poor outcome for chronic myeloid leukemia and is involved in imatinib resistance (Ping L et al. Oncol Res, February 2019) |
| Efficacy and safety of tyrosine kinase inhibitors for newly myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system (Kizaki M et al. Int J Hematol, February 2019) (epub ahead of print) |
MiR-378 promoted cell proliferation and inhibited apoptosis by enhance stem cell properties in chronic myeloid leukemia K562 cells |
| January 2019 | |
| Thrombotic microangipathy as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib (Latifi Y et al. Blood, January 2019) (epub ahead of print) |
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia: An international overview (Baccarani M et al. Leukemia, January 2019) (epub ahead of print) |
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience (Chamoun K et al. J Hematol Oncol, January 2019) |
Prediction of ALK mutations mediating ALK-TKI’s resistance and drug re-purposing to overcome the resistance (Okada K et al. E-Bio Medicine, January 2019) (epub ahead of print) |
| The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia (Lasica M et al. Leuk Lymphoma, January 2019) (epub ahead of print) |
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia: An international overview (Baccarani M et al. Leukemia, January 2019) (epub ahead of print) |
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience (Chamoun K. J Hematol Oncol, January 2019) |
New tool for monitoring molecular response in patients with chronic myeloid leukemia (Badar T et al. Appl Immunohistochem Mol Morphol, January 2019) |
|
Thrombotic microangipathy as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib |
NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia (Chang MC et al. Front immunol, January 2019) |
|
Long-term disease control in chronic myeloid leukemia |
A novel naphtoquine-coumarin hybrid that inhibits BCR-ABL1-STAT5 oncogenic pathway and reduces survival in imatinib-resistant chronic myelogenous leukemia cells (Martín-Rodríguez P et al. Front Pharmacol, January 2019) |
|
The case for real-world evidence in the future of clinical research on chronic myeloid leukemia |
Bone mesenchymal stromal cells exhibit functional inhibition but no chromosomal aberrations in chronic myelogenous leukemia (Xie J et al. Oncol Lett, January 2019) |
| Risk and challenges of CML management during pregnancy: looking for a balanced decision (Chelysheva E et al. Eur J Haematol, January 2019) (epub ahead of print) |
Twins with two different personalities: STAT5B but nocht STAT5A has a key role in BCR/ABL-induced leukemia (Kollmann S et al. Leukemia, January 2019) (epub ahead of print) |
CML Publications 2019
